Savara (NASDAQ:SVRA) Trading Up 8.1% – Here’s What Happened

Savara Inc (NASDAQ:SVRA)’s stock price traded up 8.1% during trading on Wednesday . The stock traded as high as $2.96 and last traded at $2.94. 527,976 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 881,264 shares. The stock had previously closed at $2.72.

Analyst Upgrades and Downgrades

SVRA has been the topic of several recent analyst reports. Evercore ISI reissued an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright cut their price objective on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Wells Fargo & Company began coverage on Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company. Finally, JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a research report on Thursday, December 19th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.86.

Savara Price Performance

The company has a market capitalization of $521.72 million, a P/E ratio of -7.07 and a beta of 0.68. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The business’s fifty day moving average price is $3.29 and its 200-day moving average price is $3.88.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, sell-side analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Savara

In other Savara news, Director Joseph S. Mccracken purchased 20,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the purchase, the director now directly owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. increased its stake in shares of Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after buying an additional 4,157,385 shares during the period. Nantahala Capital Management LLC grew its holdings in Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Savara by 90.5% in the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after acquiring an additional 2,165,701 shares during the period. First Light Asset Management LLC bought a new position in shares of Savara during the second quarter valued at about $8,069,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Savara by 22.9% during the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after purchasing an additional 1,608,522 shares during the period. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.